Ocugen Inc (OCGN) - Net Assets
Based on the latest financial reports, Ocugen Inc (OCGN) has net assets worth $3.53 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.60 Million) and total liabilities ($54.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OCGN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.53 Million |
| % of Total Assets | 6.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | 37.5% |
| 10-Year Change | 5.09% |
| Growth Volatility | 145.43 |
Ocugen Inc - Net Assets Trend (2012–2024)
This chart illustrates how Ocugen Inc's net assets have evolved over time, based on quarterly financial data. Also explore OCGN total assets for the complete picture of this company's asset base.
Annual Net Assets for Ocugen Inc (2012–2024)
The table below shows the annual net assets of Ocugen Inc from 2012 to 2024. For live valuation and market cap data, see OCGN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $29.63 Million | -26.95% |
| 2023-12-31 | $40.56 Million | -45.17% |
| 2022-12-31 | $73.98 Million | -22.79% |
| 2021-12-31 | $95.82 Million | +344.63% |
| 2020-12-31 | $21.55 Million | +95.58% |
| 2019-12-31 | $11.02 Million | +2505.77% |
| 2018-12-31 | $-458.00K | +95.94% |
| 2017-12-31 | $-11.27 Million | -183.05% |
| 2016-12-31 | $13.57 Million | -51.89% |
| 2015-12-31 | $28.20 Million | -47.98% |
| 2014-12-31 | $54.21 Million | +171.74% |
| 2013-12-31 | $-75.55 Million | -283.31% |
| 2012-12-31 | $-19.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ocugen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25518500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.92 Million | 9.84% |
| Other Comprehensive Income | $48.00K | 0.16% |
| Other Components | $366.89 Million | 1238.15% |
| Total Equity | $29.63 Million | 100.00% |
Ocugen Inc Competitors by Market Cap
The table below lists competitors of Ocugen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sygnity SA
WAR:SGN
|
$461.83 Million |
|
Magnum Bhd
KLSE:3859
|
$461.86 Million |
|
Top Gum Industries Ltd
TA:TPGM
|
$461.88 Million |
|
Gemtek Technology Co Ltd
TW:4906
|
$462.07 Million |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
$461.51 Million |
|
Cosmo Chem
KO:005420
|
$461.48 Million |
|
Banco de Valores SA
BA:VALO
|
$461.40 Million |
|
Shaanxi Jinye Science Technology and Education Group Co Ltd
SHE:000812
|
$461.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ocugen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,564,000 to 29,632,000, a change of -10,932,000 (-27.0%).
- Net loss of 54,054,000 reduced equity.
- Other comprehensive income increased equity by 28,000.
- Other factors increased equity by 43,094,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-54.05 Million | -182.42% |
| Other Comprehensive Income | $28.00K | +0.09% |
| Other Changes | $43.09 Million | +145.43% |
| Total Change | $- | -26.95% |
Book Value vs Market Value Analysis
This analysis compares Ocugen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-92.71 | $1.80 | x |
| 2013-12-31 | $-355.35 | $1.80 | x |
| 2014-12-31 | $2120.07 | $1.80 | x |
| 2015-12-31 | $127.87 | $1.80 | x |
| 2016-12-31 | $56.57 | $1.80 | x |
| 2017-12-31 | $-29.82 | $1.80 | x |
| 2018-12-31 | $-0.74 | $1.80 | x |
| 2019-12-31 | $0.79 | $1.80 | x |
| 2020-12-31 | $0.19 | $1.80 | x |
| 2021-12-31 | $0.49 | $1.80 | x |
| 2022-12-31 | $0.34 | $1.80 | x |
| 2023-12-31 | $0.17 | $1.80 | x |
| 2024-12-31 | $0.11 | $1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ocugen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -182.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1333.02%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 2.78x
- Recent ROE (-182.42%) is below the historical average (-81.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -65134.62% | 0.00x | 0.00x | $-14.96 Million |
| 2013 | 0.00% | -321400.00% | 0.00x | 0.00x | $-18.16 Million |
| 2014 | -42.05% | 0.00% | 0.00x | 1.21x | $-28.21 Million |
| 2015 | -113.57% | 0.00% | 0.00x | 1.30x | $-34.84 Million |
| 2016 | -119.47% | 0.00% | 0.00x | 2.66x | $-17.56 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.29 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.60 Million |
| 2019 | -183.72% | -47496.48% | 0.00x | 1.53x | $-21.34 Million |
| 2020 | -101.26% | -50748.84% | 0.00x | 1.27x | $-23.98 Million |
| 2021 | -60.91% | -254646.60% | 0.00x | 1.10x | $-67.95 Million |
| 2022 | -105.21% | -3128.38% | 0.02x | 1.47x | $-85.23 Million |
| 2023 | -155.50% | -1045.03% | 0.09x | 1.59x | $-67.13 Million |
| 2024 | -182.42% | -1333.02% | 0.05x | 2.78x | $-57.02 Million |
Industry Comparison
This section compares Ocugen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ocugen Inc (OCGN) | $3.53 Million | 0.00% | 15.30x | $461.52 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more